Arcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 2.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 579,623 shares of the company’s stock after acquiring an additional 12,644 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Arcus Biosciences were worth $8,631,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in RCUS. Quest Partners LLC lifted its position in shares of Arcus Biosciences by 40,904.3% during the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after buying an additional 9,408 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in Arcus Biosciences by 25.1% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 931,048 shares of the company’s stock worth $14,236,000 after acquiring an additional 186,750 shares during the period. Intech Investment Management LLC purchased a new position in Arcus Biosciences during the third quarter valued at $244,000. Massachusetts Financial Services Co. MA grew its position in shares of Arcus Biosciences by 39.0% in the third quarter. Massachusetts Financial Services Co. MA now owns 80,889 shares of the company’s stock valued at $1,237,000 after purchasing an additional 22,716 shares during the period. Finally, Algert Global LLC increased its stake in shares of Arcus Biosciences by 48.0% during the third quarter. Algert Global LLC now owns 112,847 shares of the company’s stock worth $1,725,000 after purchasing an additional 36,590 shares in the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Arcus Biosciences

In other news, Director Yasunori Kaneko purchased 20,000 shares of the firm’s stock in a transaction on Thursday, February 27th. The shares were bought at an average cost of $10.06 per share, for a total transaction of $201,200.00. Following the completion of the purchase, the director now directly owns 28,400 shares of the company’s stock, valued at approximately $285,704. This trade represents a 238.10 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Terry J. Rosen purchased 19,800 shares of the stock in a transaction dated Thursday, February 27th. The shares were purchased at an average price of $10.18 per share, with a total value of $201,564.00. Following the completion of the transaction, the chief executive officer now owns 2,554,160 shares of the company’s stock, valued at approximately $26,001,348.80. This trade represents a 0.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company’s stock.

Arcus Biosciences Stock Performance

NYSE:RCUS opened at $8.95 on Monday. The company’s 50-day moving average is $11.66 and its two-hundred day moving average is $14.60. Arcus Biosciences, Inc. has a 1-year low of $8.82 and a 1-year high of $19.11. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. The firm has a market capitalization of $940.46 million, a price-to-earnings ratio of -2.84 and a beta of 1.36.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($1.03) earnings per share for the quarter, topping the consensus estimate of ($1.17) by $0.14. The company had revenue of $36.00 million during the quarter, compared to analyst estimates of $29.38 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. Analysts forecast that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Analyst Upgrades and Downgrades

RCUS has been the topic of a number of research reports. Bank of America decreased their price target on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 19th. Morgan Stanley decreased their target price on Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 18th. Finally, HC Wainwright upgraded Arcus Biosciences from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $18.00 to $24.00 in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Arcus Biosciences presently has an average rating of “Buy” and a consensus target price of $30.25.

Arcus Biosciences Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.